Risk-Based Approaches to Clinical Investigations
The Risk-Based Approaches to Clinical Investigations compendia consists of conference presentation materials submitted by speakers and industry thought leaders
RELATED
- Snapshot Shows Targeted Site Monitoring Trend
- Risk-Based Approach to Monitoring
- Has FDA Guidance on Risk-based Monitoring Impacted SDV Coverage Yet?More in Risk-Based Monitoring
This Compendium consists of presentation materials submitted by speakers that complement their presentations from CBI’s Risk-Based Approaches to Clinical Investigations. CBI has provided information and networking opportunities for thousands of executives in industries such as pharmaceuticals, biotech, medical devices and managed care. We understand what an important resource this material is and we have made a concerted effort to secure biographical sketches, outlines and related materials from the conference.
View agenda from this past conference
PRESENTATIONS:
- Dean Gittleman MS, Senior Director, Operations, Target Health Inc.Read Bio
- Imogene Grimes Ph.D., Senior Director, Biostatistics, Otsuka Pharmaceutical Development & Commercialization, Inc. Read Bio
- Darlene Kalinowski, Associate Director, eDC Operations, Bristol-Myers SquibbRead Bio
- Jules T. Mitchel MBA, Ph.D., President, Target Health Inc.Read Bio
- Anne Marie Murphy, Principal, Hyman, Phelps & McNamaraRead Bio
- Mary Oster, Board Chair, New England Institutional Review BoardRead Bio
- Sharon S. Reinhard M.S., Associate Director, Compliance Operations & Oversight, Endo PharmaceuticalsRead Bio
- Vadim Tantsyura MS, MA, DrPh (c) Clinical Trial Operations Manager, Sanofi
- Vadim Tantsyura OpeningRead Bio
- Kerri Weingard NP, Research Director, Accumed Research AssociatesRead Bio
- Christian Yavorsky Ph.D. Chief Science Officer & Clinical Director, CROnos Clinical Consulting ServicesRead Bio
- Stephen Young, Senior Product Director, Medidata SolutionsRead Bio
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
